Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers specialty treatment and recovery programs derived from motor vehicle accident injuries, long-term disability cases, corporate wellness, and job-site injuries. Further, it provides cold laser therapeutics, shockwave therapy, custom bracing and orthotics, custom compression therapy/stockings, and lymphatic drainage treatment. The company offers medical technology services, such as telemedicine and remote patient monitoring. It operates 16 owned clinics, a contracted network of 102 affiliate clinics, and 220 eldercare related care homes, as well as retirement homes and community-based locations in Canada. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of ALMC-ASAP Holdings, Inc.
IPO Year:
Exchange: NASDAQ
Website: novointegrated.com
| Date | Price Target | Rating | Analyst |
|---|
DEFA14A - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
DEFA14A - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
DEF 14A - Novo Integrated Sciences, Inc. (0001138978) (Filer)
PRE 14A - Novo Integrated Sciences, Inc. (0001138978) (Filer)
S-8 - Novo Integrated Sciences, Inc. (0001138978) (Filer)
SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received confirmation of the issuance of a Standby Letter of Credit ("SBLC") by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC upon completion of monetization. The Company expects to use the proceeds to close the acquisition of the Ophir Collection which will result in the sole unfettered ownership of the Ophir Collection by the Company. "The issuance o
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase under the stock repurchase program is based on the amount, if any, of excess funds that may be generated from the pending program to monetize a Standby Letter of Credit intended to complete the Ophir Collection acquisition. Pending
Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 million, and two other partner companies investing $2.5 million Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that its wholly owned Canadian subsidiary, Acenzia Inc. ("Acenzia"), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commercialization of three consumer-ready p
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco ("RC"), have amended the prepayment terms and conditions of the previously disclosed $70,000,000 promissory note, dated April 26, 2023 (the "RC Note") to provide that, at any time after 12 months and no later than 60 months from the commencement of the term of the RC Note and prior to an event of default, if the Company's listed common stock closes over $15 per share for a period of five consecutive trading days, the Company may prepay up to 50% of the outstanding RC Note in restricted shares, at a value equal to 15% gr
As previously reported, the Board of Directors (the "Board") of Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") approved the repurchase of up to $5 million of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions (the "Stock Repurchase Program"). The Company today announced that the Board is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the Stock Repurchase Program based on the amount, if any, of excess funds that may be generated from the recently disclosed program to monetize a Standby Let
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that as part of a program to monetize a Standby Letter of Credit ("SBLC"), the Company has received written confirmation that a Ready, Willing and Able ("RWA") has been issued by HSBC, for delivery by Swift MT 760, of a SBLC. The Company previously entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million, under the SBLC instrument, on or before June 14, 2024. The intended use of the proceeds will secure the closing of the previously disclosed Purchase and Sale Agreement to acquire the Ophir Collection resulting
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the second fiscal quarter ended February 29, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 second quarter period emphasized maximizing operational efficiencies pointed towards future cost savings and margin improvement. The Company continues to work with certain prospective financial partners to close previously announced non-tradi
Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today the Company has entered into a securities purchase agreement, dated April 5, 2024, with Streeterville Capital, LLC ("Streeterville") pursuant to which the Company issued a secured convertible promissory note (the "Note") with a maturity date of April 8, 2025 in the principal sum of $6,210,000. On April 8, 2024, Streeterville paid the purchase price of $5,500,000 in exchange for the Note. On April 10, 2024, the Company repaid in full the remaining outstanding balances for bo
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
3 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
3 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic
Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today it has completed the acquisition of PRO-DIP, LLC, a U.S.-based company that has developed an innovative, patent-pending oral pouch delivery system technology which allows for broad market applications related to nutritionally focused products and medicinal based formulations. The all-share transaction is valued at $755,385, or $3.98 per share of the Company's common stock. "The acquisition of PRO-DIP is a strategically important event complimentary to one of Novo's growth initiatives to build a health science related IP portfolio," said Robert Mattacchione, Novo's Chairman and CEO. "We believe adding PRO
Shares of Tellurian Inc. (NASDAQ:TELL) rose sharply in today's pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. The implied enterprise value is around $1,200 million. Tellurian shares jumped 65% to $0.9422 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 43.8% to $0.1495 in pre-market trading after jumping more than 12% on Friday. Netcapital, last week, announced the launch of the beta version of its secondary trading platform. Serve Robotics Inc. (NASDAQ:SERV) gained 36.8% to $10.33 in pre-market trading. Serve Robotics shares jumped
On Friday, Novo Integrated Sciences Inc (NASDAQ:NVOS) announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC). The initial disbursement represents the first payment per the arrangement, creating a release of lien and resulting in the subsequent final advance to the company. With this initial disbursement, the company expects final distribution to follow on or before Aug. 2. As previously reported, the company entered into an application for the monetizing program whereby the company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program. Robert Matt
Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results. Intuitive Surgical reported second-quarter revenue of $2.01 billion, beating the consensus estimate of $1.97 billion. The robotic-assisted surgery company reported quarterly adjusted earnings of $1.78 per share, beating analyst estimates of $1.54 per share. Intuitive Surgical shares jumped 6.7% to $444.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Serve Robotics Inc. (NASDAQ:SERV) gained 68.4% to $4.43 in pre-market trading after gaining over 12% on Thursday.
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares are blasting higher Thursday after-hours after the company announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC) and monetization program. The Details: As previously reported, Novo entered into an application whereby the company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program. Novo said the initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the company. With this initial disbursement, the Novo expects f
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization
Shares of WD-40 Company (NASDAQ:WDFC) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its third quarter on Wednesday. Quarterly sales came in at $155 million which beat the analyst consensus estimate of $145.8 million. WD-40 reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.27 per share, according to data from Benzinga Pro. WD-40 shares jumped 12.5% to $247.20 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Volcon, Inc. (NASDAQ:VLCN) rose 65.8% to $6.05 in pre-market trading after declining over 6% on Wednesday. Actelis Networks, Inc.
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Mainz Biomed shares jumped 16% to $0.5534 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pineapple Energy Inc. (NASDAQ:PEGY) rose 85% to $2.22 in pre-market trading. Pineapple Energy engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 43.5% to $13.26 in pre-market trading after gaining 127% on Mon